|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The expression of these isoforms was found brain-region specific, and significant lower expression levels of both RAGEΔ and sRAGEΔ were detected in multiple brain regions of AD subjects than control subjects.
|
25912778 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
We proposed that peptide fragments from RAGE prevent negative effects of the receptor activation during AD neurodegeneration.
|
29332040 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Azeliragon is an inhibitor of the receptor for advanced glycation end products being developed for the treatment of Alzheimer's disease.
|
30934161 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
It was also observed that amyloid precursor protein, ryanodine receptor, mammalian target of rapamycin complex 1, and receptor for advanced glycation end products are associated with a worse prognosis in AD.
|
29565713 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Advanced glycation end products generated by chronic hyperglycemia and their receptor RAGE provide critical links between diabetes and AD.
|
27156888 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that the AGEs/RAGE/Rho/ROCK pathway in BV2 cells could intensify the non-specific inflammation of AD, which will provide novel strategies for the development of anti-AD drugs.
|
28284330 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, the modulation of RAGE proteolysis provides a novel intervention strategy for AD.
|
19672558 |
2009 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end-products (RAGE) is a multifunctional receptor with multiple ligands that is known to play a key role in several diseases, including diabetes, arthritis, and Alzheimer's disease.
|
18331236 |
2007 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
RAGE is involved in chronic complications of type 2 diabetes and Alzheimer's disease.
|
26745632 |
2016 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The overall variation of the haplotypes formed by the RAGE and TNF and HSP70 variants influenced the presence of the AD phenotype (omnibus association LR test p-value 0.00185), HSP701 and HSP702 showed independent effect on AD risk after adjusting for the effect of the entire haplotype (conditional LR test p-value=0.0114 and p-value=0.0044 respectively).
|
26502815 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model.
|
28205565 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, it is still debated if the interaction of Aβ with RAGE compromises the BBB function in Alzheimer' disease (AD).
|
31267346 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of Alzheimer's disease.
|
30319347 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results implicate the regulation of the Aβ-induced formation of AVs by the RAGE-calcium-CaMKKβ-AMPK pathway and suggest that modulation of autophagosome formation and the interaction between Aβ and RAGE are beneficial in the treatment and prevention of Alzheimer's disease.
|
22048125 |
2012 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggested that polymorphisms in the RAGE gene are involved in genetic susceptibility to AD.
|
27699858 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
3xTg-AD mice showed a significant decrease in body weight and an increase in postprandial glycemia, glycated hemoglobin (HbA1c), and vascular nitrotyrosine, superoxide anion (O2•-), receptor for the advanced glycation end products (RAGE) protein, and monocyte chemoattractant protein-1 (MCP-1) levels when compared to WT mice.
|
25471187 |
2015 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Reduced RAGE mRNA in mononuclear blood cells of patients with probable Alzheimer disease.
|
18427074 |
2008 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains.
|
18431028 |
2007 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The striking reduction of circulating sRAGE in Alzheimer disease further supports a role for the RAGE axis in this clinical entity and requires further investigation.
|
16286548 |
2005 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.
|
18657529 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Therapeutic
|
disease |
RGD |
Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus.
|
23396166 |
2013 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
RGD |
Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus.
|
23396166 |
2013 |